

In the Claims:

Applicant presents a full set of claims for the convenience of the Examiner. No claim amendments have been made.

1. (Previously presented) An isolated polypeptide comprising an unbroken sequence of amino acids from SEQ ID NO:1 that complexes with a major histocompatibility complex molecule type HLA-A2, wherein the amino acid sequence of said isolated polypeptide is not that set out in either of SEQ ID NOs:1 and 2, or that coded for by nucleotides 334-918 of SEQ ID NO:7, or GLEGAQAPL (SEQ ID NO:50), or FLLFKYQMK (SEQ ID NO:48), or FIEGYCTPE (SEQ ID NO:49).
2. (Previously presented) An isolated polypeptide comprising an unbroken sequence of amino acids from SEQ ID NO:1, that elicits an immune response from human lymphocytes, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in either of SEQ ID NOs:1 and 2, or that coded for by nucleotides 334-918 of SEQ ID NO:7, or GLEGAQAPL (SEQ ID NO:50).
3. (Canceled)
4. (Previously presented) A nonapeptide comprising an unbroken sequence of amino acids from SEQ ID NO:1, wherein the amino acid adjacent to the N-terminal amino acid is L or M, and the C-terminal amino acid is L, V, or I, other than a nonapeptide having the sequence CLGLSYDGL (SEQ ID NO:57), or GLEGAQAPL (SEQ ID NO:50).
5. (Previously presented) A nonapeptide as claimed in claim 4, wherein the amino acid in position 3 is Y and/or the amino acid in position 4 is D and/or the amino acid in position 5 is G and/or the amino acid in position 7 is E and/or the amino acid in position 8 is H.
- 6.-8. (Canceled)

9. (Previously presented) A nonapeptide having the amino acid sequence GLYDGMEHL (SEQ ID NO:42) or GLYDGREHS (SEQ ID NO:43).
10. (Withdrawn) A decapeptide having the amino acid sequence GLYDGMEHLI (SEQ ID NO:44) or GLYDGREHSV (SEQ ID NO:45).
11. (Previously presented) An isolated polypeptide of up to about 93 amino acids in length, characterised by comprising a nonapeptide as claimed in claim 4.
- 12.-41. (Canceled)
42. (Previously presented) The nonapeptide of claim 4, wherein the amino acid adjacent to the N-terminal amino acid is L.
43. (Previously presented) The nonapeptide of claim 4, wherein the C-terminal amino acid is L.
44. (Previously presented) The isolated polypeptide of claim 1, the polypeptide being a nonapeptide wherein the amino acid adjacent to the N-terminal amino acid is L or M, and the C-terminal amino acid is L, V, or I.
45. (Previously presented) The isolated polypeptide of claim 44, wherein the amino acid adjacent to the N-terminal amino acid is L.
46. (Previously presented) The isolated polypeptide of claim 44, wherein the C-terminal amino acid is L.
47. (Previously presented) The isolated polypeptide of claim 2, the polypeptide being a nonapeptide wherein the amino acid adjacent to the N-terminal amino acid is L or M, and the C-terminal amino acid is L, V, or I.

48. (Previously presented) The isolated polypeptide of claim 47, wherein the amino acid adjacent to the N-terminal amino acid is L.
49. (Previously presented) The isolated polypeptide of claim 47, wherein the C-terminal amino acid is L.
50. (Canceled)
51. (Withdrawn) A decapeptide comprising the nonapeptide of claim 44.
52. (Previously presented) The isolated polypeptide of claim 1, wherein the polypeptide elicits an immune response from human lymphocytes.
53. (Previously presented) The isolated polypeptide of claim 52, wherein the polypeptide elicits an immune response from human lymphocytes when complexed with a major histocompatibility complex molecule type HLA-A2.
54. (Previously presented) The isolated polypeptide of claim 52, wherein the immune response is a cytolytic response from human T-lymphocytes.
55. (Previously presented) The isolated polypeptide of claim 1, wherein the major histocompatibility complex molecule type HLA-A2 is HLA-A2.1.